Prop. 71 will generate a total of at least $6.4 to $12.6 billion in new state revenues

The San Diego Regional Chamber of Commerce and the Contra Costa Council, two of the State's leading regional business advocacy organizations, today announced their endorsements of Proposition 71, the California Stem Cell Research and Cures Initiative.

Proposition 71, which appears on the November 2004 ballot, will provide funds needed for the development of lifesaving therapies and cures for diseases that could save the lives of millions of California children and adults and reduce health care costs.

The life-science/biotech sector is a backbone of California's economy. According to a 2004 report authored by the California Healthcare Institute, "More than 230,000 Californians work in the biomedical industry, which paid more than $14 billion in wages and salaries."

The San Diego Regional Chamber of Commerce and the Contra Costa Council join many of the State's leading business organizations, including the California Chamber of Commerce, Tri Valley Council, San Jose/Silicon Valley Chamber of Commerce, San Francisco Chamber of Commerce, Los Angeles Business Council, Black Chamber of Commerce, Greater Los Angeles African American Chamber of Commerce, Los Angeles Area Chamber of Commerce, Valley Industry & Commerce Association, Hispanic Chamber of Commerce, and Latin Business Association. In addition, the State's top fiscal officers, Controller Steve Westly and Treasurer Phil Angelides, have endorsed the measure. Former economic advisor to President Ronald Reagan and current Hoover Institution Distinguished Fellow George Shultz is also supporting Prop. 71.

A recent economic study, co-authored by a nationally-recognized economic research firm, the Analysis Group, and Stanford professor and economist Dr. Laurence Baker, has determined that Prop. 71 will generate a total of at least $6.4 to $12.6 billion in new state revenues and health care cost savings during the payback period, providing a return on investment of at least 120% to 236%.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer